EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics

Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Andrea Ortiz Rocha, Anu Sharma, Diana Barb, Nathaly Cuervo-Pardo, Kelly Y Chun, Toni R Prezant, Margery A Connelly, Jens T Rosenberg, Joseph R Grajo, Fernando Bril iD und 1 weitere

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70799 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Srilaxmi Kalavalapalli und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida, Gainesville Florida, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Liver Cirrhosis, Fatty Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Metabolic dysfunction‐associated steatohepatitis (MASH) is a leading cause of cirrhosis. NIS2+ is a recently approved serum‐based test combining two biomarkers (miR‐34a‐5p and YKL‐40) to identify at‐risk MASH (i.e., MASH and significant fibrosis).

Objective

To assess the prevalence of at‐risk MASH by NIS2+ in individuals from primary care or endocrinology clinics. Materials and Methods 798 participants recruited from outpatient clinics were risk‐stratified by NIS2+ into low‐risk, intermediate‐risk or having at‐risk MASH (NIS2+ score < 0.46, ≥ 0.46 and < 0.68 or ≥ 0.68, respectively). Presence of steatosis (CAP ≥ 288 dB/m) and clinically significant liver fibrosis (VCTE‐ ≥ 8.0 kPa) was established by transient elastography (FibroScan).

Results

At‐risk MASH affected 29% of individuals with both obesity and T2D compared to 3% of those without either condition ( p < 0.001). People with at‐risk MASH, compared to those at low‐risk, more often had steatosis (81% vs. 40%), clinically significant fibrosis (42% vs. 5%), AST or ALT ≥ 40 IU/L, hepatic insulin resistance (by HOMA‐IR) and adipose tissue insulin resistance (by adipo‐IR) (all p < 0.001). NIS2+ strongly correlated with diagnosis of at‐risk MASH by FAST ( r = 0.67; p < 0.001), as well as CK‐18, ALT and AST and liver fibrosis by VCTE‐LSM (all p < 0.001).

Conclusion

The prevalence of at‐risk MASH is high in individuals with obesity and T2D attending outpatient primary care and endocrinology clinics. Their progression to cirrhosis may be prevented with early risk‐stratification and timely intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseLiver CirrhosisFatty LiverHumansBiomarkersChitinase-3-Like Protein 1MicroRNAsAmbulatory Care FacilitiesEndocrinologyObesityDiabetes Mellitus, Type 2Risk FactorsCross-Sectional StudiesAdultMiddle AgedAgedMaleFemale

Stichwörter der Autor:innen

MASHMASLDNIS2+T2DVCTE‐LSMliver fibrosismetabolic dysfunction‐associated steatohepatitismetabolic dysfunction‐associated steatotic liver diseaseobesitytype 2 diabetes

Substanzen

BiomarkersCHI3L1 protein, humanMIRN34 microRNA, humanChitinase-3-Like Protein 1MicroRNAs

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida, Gainesville Florida, USA.
  • Labcorp, Calabasas, California, USA.
  • Labcorp, Morrisville, North Carolina, USA.
  • Advanced Magnetic Resonance Imaging and Spectroscopy Facility, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA.
  • Department of Radiology, University of Florida College of Medicine, Gainesville, Florida, USA.
  • Division of Endocrinology, Diabetes and Metabolism, University of Alabama, Birmingham, USA.

ORCID-Profile: Fernando Bril, Kenneth Cusi

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Kalavalapalli, S., Leiva, E. G., Rocha, A. O., Sharma, A., Barb, D., Cuervo-Pardo, N., Chun, K. Y., Prezant, T. R., Connelly, M. A., Rosenberg, J. T., Grajo, J. R., Bril, F., & Cusi, K. (2026). High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70799

Vancouver

Kalavalapalli S, Leiva EG, Rocha AO, Sharma A, Barb D, Cuervo-Pardo N, et al. High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70799

BibTeX
@article{Kalavalapalli2026,
  author = {Kalavalapalli, Srilaxmi and Leiva, Eddison Godinez and Rocha, Andrea Ortiz and Sharma, Anu and Barb, Diana and Cuervo-Pardo, Nathaly and Chun, Kelly Y and Prezant, Toni R and Connelly, Margery A and Rosenberg, Jens T and Grajo, Joseph R and Bril, Fernando and Cusi, Kenneth},
  title = {High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70799}
}
Kostenlos starten →